For the first time in thirteen years the Federal Drug Administration approved a new drug, Yervoy, that has been shown to extend the survival rate in patients with late-stage melanoma!  Yervoy, also known as ipilimumab was developed by Bristol-Myers Squibb. The “yes” was given on March 25, 2011 after the results of  an international study of 676 end-stage melanoma patients was received. The study showed that Yervoy increased the survival rate of melanoma patients from six months to ten months. …